Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...

The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...

Patients with low-grade upper tract urothelial carcinoma who achieved a complete response after receiving treatment with UGN-101 experienced a clinically meaningful long-term response, with a median ...

Patients with bone-protecting agent use versus no bone-protecting agent had similar baseline characteristics: ...

The first 24 patients who received treatment with cretostimogene and were evaluated for high-grade recurrence-free survival and safety were evaluated. Kaplan-Meier estimates at 3- and 9-month ...

As of September 2025, 15 patients have been recruited across 8 centers. Spain, Belgium, and Ireland, with 15 centers, will be open for inclusion in Q4 of 2025, with 9 more centers in France also being ...

In patients with mHSPC, darolutamide consistently showed high efficacy, a similar incidence of treatment emergent adverse events to placebo, with similar or numerically lower treatment discontinuation ...

Zachary Klaassen hosts Luis Salgado to discuss metastasis-directed therapy for low-volume hormone-sensitive prostate cancer. The conversation highlights the challenge of interpreting disease volume in ...

Biochemical recurrence (BCR) after radical prostatectomy (RP) remains a clinical challenge, with significant heterogeneity in outcomes and optimal management strategies. Salvage radiotherapy (sRT) is ...

At the 2025 UCSF-UCLA PSMA Conference, Thomas Hope challenges using PSMA PET/CT for restaging during radioligand therapy, advocating instead for post-treatment SPECT/CT imaging. While both modalities ...

Login to update email address, newsletter preferences and use bookmarks.

At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman discusses his team's work with Terbium-161 in the VIOLET clinical trial at Peter Mac. He explains Terbium-161 offers both beta and Auger electron ...